
Opinion|Videos|August 22, 2024
Navigating CML: Tools to Empower Patients and Caregivers
Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.
Advertisement
Episodes in this series

This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- As a patient advocate, how do you help newly diagnosed CML patients and their caregivers navigate the complexities of the diagnosis and set appropriate care goals? What are some of the biggest challenges patients may face at this stage?
- What resources or educational materials have you found most helpful in supporting newly diagnosed CML patients and their caregivers?
- How do patients typically use these materials? How have you changed your approaches so patients and caregivers can best leverage these materials?
Advertisement
Related to this article

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5

